Federated Hermes’s Kalaris Therapeutics KLRS Stock Holding History

Federated Hermes’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$196	Buy	+34	New	+$302	﹤0.01%	2041
2025 Q4	–	Sell	-578	Closed	-$3.34K	–	2251
2025 Q3	$3.34K	Sell	578 -56	-9%	-$185	﹤0.01%	1979
2025 Q2	$1.69K	Hold	634	–	–	﹤0.01%	1966
2025 Q1	$5.09K	Buy	634 +59	+10%	+$578	﹤0.01%	1873
2024 Q4	$5.55K	Hold	575	–	–	﹤0.01%	1889
2024 Q3	$10.7K	Sell	575 -87	-13%	-$1.52K	﹤0.01%	1803
2024 Q2	$11K	Buy	662 +1	+0.2%	+$18	﹤0.01%	1769
2024 Q1	$11.5K	Buy	661 +576	+678%	+$9.4K	﹤0.01%	1766
2023 Q4	$1.34K	Buy	+85	New	+$3.35K	﹤0.01%	1956
2022 Q3	–	Sell	-6	Closed	-$1K	–	2258
2022 Q2	$1K	Sell	6 -5,532	-100%	-$580K	﹤0.01%	2100
2022 Q1	$860K	Buy	+5,538	New	+$1.1M	﹤0.01%	1298

Other funds holding KLRS

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Federated Hermes's KLRS Position: Q1 2026 in Review

Federated Hermes opened a new position in Kalaris Therapeutics (KLRS) in Q1 2026: 34 shares worth $196. The stake represents ﹤0.01% of the portfolio and ranks #2041 among its holdings. This is a return to the name: Federated Hermes previously reported a position in KLRS as recently as Q3 2025.

Federated Hermes first reported a position in KLRS in Q1 2022 and has held it in 11 quarters since. The position peaked at $860K in Q1 2022. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

Federated Hermes held 34 shares of Kalaris Therapeutics worth $196 as of Q1 2026.
Kalaris Therapeutics was a new Federated Hermes position in Q1 2026.
Kalaris Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #2041 holding.
Federated Hermes first reported a position in Kalaris Therapeutics in Q1 2022 and has held it in 11 quarters since.
Federated Hermes's Kalaris Therapeutics position peaked at $860K in Q1 2022.
58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.